Publicacións en colaboración con investigadores/as de Universitat Rovira i Virgili (2)

2024

  1. PCSK9 inhibitors on the management of primary and secondary cardiovascular prevention

    Lipids in Health and Disease , Vol. 23, Núm. 1

2023

  1. PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk

    International Journal of Molecular Sciences, Vol. 24, Núm. 3